BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69debceda0b10
DTSTAMP:20260414T181717
DTSTART:20150313T113000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20150313T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/552111-isotopes-for-s
 cience-and-medicine-a-summary-of-triumfs-efforts-to-advance-the-field-of-i
 sotope-production-paul-schaffer-triumf
LOCATION:Université de Montréal - Pavillon Roger-Gaudry\, 2900\, chemin d
 e la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Isotopes for Science and Medicine - A Summary of TRIUMF's  efforts 
 to advance the field of isotope production - Paul Schaffer (TRIUMF)
DESCRIPTION:Conférence de Paul Schaffer (TRIUMF)With the imminent shutdown
  of some of the world's largest isotope production reactors and the numbe
 r of small (<24 MeV) cyclotrons approaching 1000 machines in over 70 coun
 tries around the globe\, the time is ripe to establish accelerators as a 
 viable source of radionuclides. TRIUMF seeks to address looming shortages
  of important single photon-(SPECT) and positron emission- (PET) clinical 
 isotopes such as Tc-99m and to pursue promising new applications for isot
 opes including Zr-89\, Ga-68\, Y-86 and Sc-44 that are of increasing inte
 rest to chemists\, biologists and medical researchers. Isotopes both for 
 diagnosis and therapy of a variety of diseases are being studied.Typicall
 y\, Tc-99m is made available via a generator through the decay of Mo-99\,
  which originates from nuclear reactors. Canada has long played a pivotal
  role in the Mo-99 supply with a capacity of producing 80% of the world's
  demand from the (Chalk River) NRU reactor. This reactor is scheduled to 
 cease isotope production activity in 2016 and an alternative production m
 ethod is needed. TRIUMF\, in collaboration with four other Canadian insti
 tutions is leading the effort to produce Tc-99m directly on small cyclotr
 ons via the Mo-100(p\,2n) reaction. Recent successes have seen 30 Ci (111
 0 GBq) of Tc-99m produced in a single 6 hr irradiation on a 450 µA TR30 c
 yclotron (at 24 MeV) at TRIUMF. This is sufficient to supply the province
  of British Columbia on a daily basis. Our goal is to enable remaining Ca
 nadian cyclotron centres to provide Tc-99m for their respective surroundi
 ng areas.In addition to large-scale production of radiometallic isotopes u
 sing solid target materials\, research at TRIUMF seeks to investigate the
  use of liquid targets to produce research quantities of Zr-89\, Ga-68\, 
 Sc-44 and Y-86 by irradiating salt solutions of the appropriate starting 
 material. To date\, we have produced mCi (MBq) quantities of these isotop
 es. With this new approach\, we hope to open the door for the development
  of novel radiopharmaceuticals that maintain a more appropriate match bet
 ween the physical half-life of the isotopic tag and the pharmacokinetic p
 rofile of targeting vector. Our efforts in adapting liquid cyclotron targ
 ets for the purpose of producing radiometals will be discussed.Finally\, 
 a brief discussion will ensue on efforts to apply Isotope Separation On-L
 ine (ISOL) infrastructure within the ISAC facility at TRIUMF for the isol
 ation of radiotherapeutic isotopes. Progress on the isolation of At-211 (
 via Rn-211 decay) and Ac-225 will be presented. Both At-211 and Ac-225 ar
 e alpha-emitting isotopes with the potential to treat micro-metastases an
 d/or monocellular malignancies such as leukemia. TRIUMF seeks to demonstr
 ate and enable clinical trials with these and many other potentially usef
 ul radiotherapeutic isotopes available through its existing science progr
 am.Cette conférence s'adresse à tous\, y compris les professeurs\, les c
 hercheurs et les étudiants des trois cycles.Le café est servi à partir 
 de 11h20.
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR